N 3 (188) 2024. P. 52–56

CHARACTERISTICS OF HEMOSTASIS INDICATORS AND INFLAMMATION MARKERS IN WOMEN OF REPRODUCTIVE AGE WITH ADENOMYOSIS IN POST-COVID PERIOD

M. B. Zaporozhchenko, G. F. Stepanov, A. V. Bulhar

Odesa National Medical University, Odesa, Ukraine

DOI 10.32782/2226-2008-2024-3-9

Introduction. In adenomyosis, microcirculatory disorders have been proven to characterize a chronic immunoinflammatory process in the endometrium and myometrium. These processes are especially severe in the setting of a viral load, thus the issue of the course of adenomyosis after COVID-19 has become relevant. The pathogenicity of the COVID-19 virus is due to its tropism to the epithelium of endothelial cells, which is realized in endothelial damage: the latter loses antithrombogenic properties, vascular wall permeability increases, and blood procoagulant properties and the synthesis of proinflammatory cytokines raise. Against the background of the inflammatory process in the endothelium, the blood coagulation cascade is initiated.

The aim of the study was to investigate and compare the levels of blood coagulation system parameters and markers of inflammatory processes in women with adenomyosis in the post-COVID period during 3, 6, and 12 months after COVID-19.

Materials and methods. The study included 180 women of reproductive age, including 60 apparently healthy women (group A), including 30 women with COVID-19 (group A2), 120 women with adenomyosis who had COVID-19, including 60 with adenomyosis of I–II severity level (group B), and 60 with adenomyosis of III–IV severity level (group C). Blood coagulation parameters (platelets, PT, APTT, INR, fibrinogen, D-dimer) and inflammatory markers (CRP, ferritin, procalcitonin) were determined.

Results and discussion. The data obtained indicated the presence of hypercoagulability in women with COVID-19 (group A2), and more pronounced signs of hypercoagulation were determined in women with adenomyosis (groups B and C). Identical dynamics was observed in the determination of inflammatory markers between groups A2, B and C, which confirms the inflammatory process in tissues, including uterine tissue, which is also confirmed by clinical symptoms of adenomyosis in the post-COVID period.

Key words: adenomyosis, post-COVID period, hemostasis, inflammatory markers.

ЛІТЕРАТУРА

  1. Bakun OV, Tkachuk AI. Influence of genital endometriosis and concomitant diseases on infertility under the data of the retrospective analysis of casehistories. Bukovinian Medical Herald. 2019; 4(92): 9–15. doi: 10.24061/2413-0737. XXIV.4.92.2019.83 (in Ukrainian).
  2. Medvedіev MV, Pokrovenko DA. A modern view of the etiology, pathogenesis and diagnostic possibilities of external genital endometriosis (literature review). Medical perspectives. 2019; 1(24): 21–30. doi: 10.26641/2307-0404.2019.1.1621 73 (in Ukrainian).
  3. Honcharenko GY. The role of estrogen and progesterone receptors in women with adenomyosis in post menopause. Reports of Vinnytsia National Medical University. 2019; 1(23): 148–152. doi: 10.31393/reports-vnmedical-2019-23(1)-26 (in Ukrainian).
  4. Tatarchuk TF, Zakharenko NF, Reheda SI et al. Algorithms for prescribing menopausal hormone therapy in different periods of menopause. Reproductive Endocrinology. 2022; 4(66): 68–70. doi: 10.18370/2309-4117.2022.66.68-70 (in Ukrainian).
  5. Yan Y, Zhang X, Zhong D, et al, Adenomyosis-Associated Ischemic Stroke: Pathophysiology, Detection and Management. Brain Sci. 2022; 12(10): 1410. doi: 10.3390/brainsci12101410.
  6. Habiba M, Guo SW, Benagiano G. Adenomyosis and Abnormal Uterine Bleeding: Review of the Evidence. 2024 May 23; 14(6): 616. doi: 10.3390/biom14060616.
  7. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020 Nov; 100: 327–332. doi: 10.1016/j.ijid.2020.09.016.
  8. Ma H, Hong M, Duan J, et al. Altered cytokine gene expression in peripheral blood monocytes across the menstrual cycle in primary dysmenorrhea: a case-control study. PLoS One. 2013; 8(2): e55200. doi: 10.1371/journal.pone.0055200.
  9. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May; 18(5): 1094–1099. doi: 10.1111/jth.14817.
  10. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021 Apr; 27(4): 626–631. doi: 10.1038/s41591-021-01292-y. Epub 2021 Mar 10. Erratum in: Nat Med. 2021 Jun; 27(6): 1116. doi: 10.1038/ s41591-021-01361-2.
  11. Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers: Preliminary Findings. Pediatr Dev Pathol. 2020 May–Jun; 23(3): 177–180. doi: 10.1177/1093526620925569.
  12. Ramos da Silva S, Ju E, Meng W, et al. Broad Severe Acute Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues from Fatal Coronavirus Disease 2019. J Infect Dis. 2021 Jun 4; 223(11): 1842–1854. doi: 10.1093/infdis/jiab195.
  13. Del Turco S, Vianello A, Ragusa R, et al. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Thromb Res. 2020 Dec; 196: 143–151. doi: 10.1016/j.thromres.2020.08.039.
  14. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE); 2020 Dec 18. PMID: 33555768.
  15. Grobler C, Maphumulo SC, Grobbelaar LM, et al. Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. Int J Mol Sci. 2020 Jul 21; 21(14): 5168. doi: 10.3390/ijms21145168.
  16. Plummer AM, Matos YL, Lin HC, et al. Gut-brain pathogenesis of post-acute COVID-19 neurocognitive symptoms. Front Neurosci. 2023 Sep 28; 17: 1232480. doi: 10.3389/fnins.2023.1232480.
View article PDF